
Monday, March 30, 2020 1:56:10 AM
https://www.astrazeneca.com/media-centre/articles/2020/our-update-on-covid-19.html
PUBLISHED
13 March 2020
AstraZeneca is responding to the COVID-19 (novel coronavirus) outbreak, consistent with our values to follow the science, put patients first and do the right thing. Our priorities are to ensure the continued supply of our medicines to patients, and to safeguard the health and wellbeing of all our employees and communities.
Our medicines supply chain is robust, and we continue to monitor the situation closely. Our stringent quality management system ensures the safety, quality and efficacy of all our medicines at all times.
As a science-led biopharmaceutical company, our clinical research is crucial to the development of innovative new medicines, and we have taken appropriate measures to ensure continuity and mitigate any impact to our research and development programmes.
To help protect the health and wellbeing of our 70,000 employees around the world and the communities in which we operate, we have implemented temporary measures to help reduce the risk of infection. These include leveraging digital technology to support working-from-home, as well as restricting business travel, off-site meetings and external visitors to AstraZeneca sites. Our guidance is aligned with local government authorities.
AstraZeneca is engaging with international health authorities and governments in response to the outbreak. We have provided our science and technology expertise to authorities including the World Health Organization (WHO) and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Through our scientific expertise in infectious disease and proprietary antibody discovery technology, we have rapidly mobilised our research efforts to discovering novel coronavirus-neutralising antibodies as a treatment to prevent COVID-19 disease. Our teams are now focused on identifying monoclonal antibodies to progress into clinical trial evaluation. We look forward to providing more updates on our research soon.
C4urself the 1st Ammendment.
Don't assume that i don't know, and i wont assume, that you have no idea.
Liked By
Spread the love. Be the first to like this post!
Recent AZNCF News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/25/2023 04:49:01 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/20/2023 10:55:28 AM
- Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities • Edgar (US Regulatory) • 08/16/2023 08:09:15 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/17/2023 06:08:46 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/03/2023 05:35:37 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/03/2023 12:30:26 PM
FEATURED 1606 Corp. Partners with Cool Blue To Launch ChatCBD, a New AI Customer Experience • Sep 26, 2023 8:37 AM
Branded Legacy Inc. Invests Heavily in Innovation and Growth with $540,000 Expansion • BLEG • Sep 26, 2023 10:37 AM
Avant Technologies Reshaping Future of Supercomputing and AI with Disruptive Private Cloud Infrastructure • AVAI • Sep 26, 2023 8:45 AM
Image Protect Announces Debt Forgiveness in Excess of $1,400,000 Clearing the Path for Pending New Business Development • IMTL • Sep 26, 2023 8:16 AM
CGrowth Capital Inc. Nears Key Milestone in Lithium Mining Expansion • CGRA • Sep 26, 2023 8:08 AM
Green Egg to launch $150 million bond offer for quicklime products production kiln plant Sep 22, 2023 12:11 PM